Lević, Z.M. (7003341242)Z.M. (7003341242)LevićDujmović, I. (6701590899)I. (6701590899)DujmovićPekmezović, T. (7003989932)T. (7003989932)PekmezovićJarebinski, M. (7003463550)M. (7003463550)JarebinskiMarinković, J. (7004611210)J. (7004611210)MarinkovićStojsavljević, N. (6603086728)N. (6603086728)StojsavljevićDrulović, J. (6603831498)J. (6603831498)Drulović2025-07-022025-07-021999https://doi.org/10.1177/135245859900500306https://www.scopus.com/inward/record.uri?eid=2-s2.0-0033043478&doi=10.1177%2f135245859900500306&partnerID=40&md5=75a90c9108b2e896c9dd239986dc877fhttps://remedy.med.bg.ac.rs/handle/123456789/14464In a hospital-based study of 119 patients with definite multiple sclerosis, demographic and clinical factors were analysed with respect to their validity in assessing the long-term prognosis. Over a mean follow-up of 21.7 years, the following factors negatively influenced the prognosis by the univariate analysis: male sex, age at onset over 25, pyramidal involvement or spasticity at onset, ≥ 3 functional systems affected at onset or after 5 years, incomplete first remission, length of the first remission ≤ 1 year, > 5 attacks in the first 10 years, secondary or primary-progressive disease, time to reach secondary progression over 5 years and time to reach EDSS 6 over 7 years. The multivariate model showed that in patients with relapsing-remitting disease, 5 years after onset, pyramidal involvement at onset and shorter time to reach EDSS 6 predicted poor outcome, while after 10 years, higher age at onset and incomplete first remission indicated poor prognosis. Ten years after onset, the predictors of poor outcome in the secondary-progressive group were shorter time to reach EDSS 6 or secondary progression and higher EDSS, while in the primary-progressive group those variables were spasticity or higher number of functional systems affected at onset, and higher EDSS after 5 and 10 years.Clinical featuresCourseDemographic featuresMultiple sclerosisMultivariate analysisPrognosisSurvival analysisPrognostic factors for survival in multiple sclerosis